Status | Study |
Active, not recruiting |
Study Name: Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Condition: Fallopian Tube Clear Cell Adenocarcinoma Fallopian Tube Endometrioid Adenocarcinoma Date: 2010-02-23 Interventions: Drug: Bortezomib Given IP |
Completed |
Study Name: Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin Condition: Brenner Tumor Fallopian Tube Cancer Ovarian Clear Cell Date: 2009-10-09 Interventions: Drug: belinostat Given IV |
Active, not recruiting |
Study Name: Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Condition: Malignant Ovarian Mixed Epithelial Tumor Ovarian Brenner Tumor Date: 2009-08-01 Interventions: Biological: Bevacizumab Given |
Completed |
Study Name: A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Condition: Fallopian Tube Carcinoma Malignant Ovarian Mixed Epithelial Tumor Date: 2009-07-14 Interventions: Biological: Urokinase-Derived Peptide A6 |
Completed |
Study Name: Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Condition: Chemotherapeutic Agent Toxicity Endometrial Adenocarcinoma Date: 2008-12-20 Interventions: Drug: Paclitaxel Given IV or i |
Active, not recruiting |
Study Name: Selumetinib in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer Condition: Borderline Ovarian Surface Epithelial-stromal Tumor Ovarian Serous Cys Date: 2007-10-22 Interventions: Drug: selumetinib Given PO |
Completed |
Study Name: Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy Condition: Brenner Tumor Fallopian Tube Cancer Ovarian Clear Cell Date: 2007-04-25 Interventions: Biological: sargramostim Given |
Active, not recruiting |
Study Name: Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer Condition: Fallopian Tube Cancer Ovarian Clear Cell Cystadenocarcinoma Date: 2006-07-26 Interventions: Biological: denileukin diftitox |
Completed |
Study Name: Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Condition: Brenner Tumor Fallopian Tube Cancer Ovarian Clear Cell Date: 2004-03-08 Interventions: Procedure: adjuvant therapy Drug: paclitax |
Completed |
Study Name: Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma Condition: Brenner Tumor Fallopian Tube Cancer Ovarian Clear Cell Date: 2003-05-06 Interventions: Drug: paclitaxel Given IV |